Angel Invest Boston

Sponsored by Peter Fasse of Fish & Richardson: https://www.fr.com/team/j-peter-fasse/ To Join Sal's Syndicate: Click Here A terrible error in a lab led Tim Spong to start a company to improve the reliability and efficiency of pathology labs; big industry players are noticing. This interview was part of my due diligence on Tim’s startup, VistaPath Bio. Subsequently, I invested in the company. Highlights include: Sal Daher Introduces Tim Spong, Co-Founder of VistaPath Bio “Fast forward a hundred years, even if you walked into some of the best labs in the country, it's still a room full of people cutting tissue and staining tissue and sitting over jars.” “…VistaPath is really aiming to do is build the next generation pathology lab using automation, AI, advanced imaging practices, and then put that into every lab in the world…” “The rest of the time and a lot of the costs is spent in these labs, in histology labs, making the slides so that a pathologist can render a diagnosis.” The Horror Story that Motivate